

PTO/SB/21 (01-08)

Approved for use through 02/29/2008. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/593,134
	Filing Date	March 4, 2005
	First Named Inventor	Michael A. Ellsworth
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	18	Attorney Docket Number PC32199A

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): See Remarks section below
Remarks Other Enclosure(s): Renewed Petition Under 37 CFR 1.137(b) Consent of Assignee to Correction and/or Addition to Previously Named Inventors Statement in Support of Petition to Correct Inventorship in a US National Stage Application Application Data Sheet Return Receipt Postcard		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name			
Signature			
Printed name	Timothy J. Gumbleton		
Date	February 21, 2008	Reg. No.	54,143

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2008

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

130.00

## Complete if Known

Application Number 10/593,134  
 Filing Date March 4, 2005  
 First Named Inventor Michael A. Ellsworth  
 Examiner Name  
 Art Unit  
 Attorney Docket No. PC32199A

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify):

☒ Deposit Account Deposit Account Number: 16-1445 Deposit Account Name: Pfizer Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee  
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## FEE CALCULATION

## 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	310	155	510	255	210	105	
Design	210	105	100	50	130	65	
Plant	210	105	310	155	160	80	
Reissue	310	155	510	255	620	310	
Provisional	210	105	0	0	0	0	

## 2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	210	105
Multiple dependent claims	370	185
<b>Total Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>
- 20 or HP =	x	=
HP = highest number of total claims paid for, if greater than 20.		
<b>Indep. Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>
- 3 or HP =	x	=
HP = highest number of independent claims paid for, if greater than 3.		

## 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$260 (\$130 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$)

- 100 = / 50 = (round up to a whole number) x =

## 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Renewed Petition processing fee under 37 CFR 1.17(i)

Fees Paid (\$)

130.00

## SUBMITTED BY

Signature

Timothy J. Gumbleton

Registration No. 54,143  
(Attorney/Agent)

Telephone 269-833-2501


Name (Print/Type)

Timothy J. Gumbleton

Date 2-21-2008

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b> Applicant(s): Michael A. Ellsworth, et al.		Docket No. PC32199A	
Serial No. 10/593134	Filing Date 4-Mar-2005	Examiner	Group Art
<b>Invention:</b>  METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION			
<p>I hereby certify that this <u>Renewed Petition Under 37 CFR 1.137(b)</u> <span style="display: block; text-align: center;"><small>(Identify type of correspondence)</small></span></p> <p>Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450</p> <p>on <u>February 21, 2008</u> <span style="display: block; text-align: center;"><small>(Date)</small></span></p> <div style="text-align: right; margin-top: 20px;"><p><u>Cindy Malocha</u> <small>(Typed or Printed Name of Person Mailing Correspondence)</small></p><p><u></u> <small>(Signature of Person Mailing Correspondence)</small></p><p><u>EQ 934302662 US</u> <small>("Express Mail" Mailing Label Number)</small></p></div>			
<b>Note: Each paper must have its own certificate of mailing</b>			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Serial Number: 10/593,134  
Int'l Serial Number: PCT/IB2005/000610  
Priority Date: 17 March 2004  
Int'l Filing Date: 4 March 2005  
First Named Inventor: Michael A. Ellsworth  
Atty Docket Number: PC32199A  
For: METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION  
Dated: 21 February 2008

OFFICE OF PCT LEGAL ADMINISTRATION  
Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RENEWED PETITION UNDER 37 CFR 1.137(b)**

02/25/2008 LLANDGRA 00000061 161445 10593134

01 FC:1464 Sir: 130.00 DA

In a paper entitled "Decision on Petition (37 CFR 1.137(b)) dated 17 January 2008 (Hereinafter, the "Decision"), it is stated that "Applicants' petition for revival under 37 CFR 1.137(b) is DISMISSED without prejudice for failure to satisfy all the requirements of a grantable petition. If reconsideration on the merits of this petition is desired, a proper response must be filed within TWO (2) MONTHS from the mail date of this decision." This Response is filed to satisfy the requirements of a grantable petition.

A grantable petition under this section must include: (1) the required reply, unless previously filed; (2) the petition fee required by law; (3) a statement that the "entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional;" and (4) any terminal disclaimer and fee required pursuant to 37 CFR 1.137(c).

**Item 1. Required Reply.** In order for the petition to be grantable, applicants are required to file a proper response, which must include "the materials required to complete the "required reply," that is, a grantable request under 37 CFR 1.497(d) to correct the inventorship herein to include Maurice Daniel GIVENS (so as to permit acceptance of the revised declaration filed 12 December 2007)." The requirements for the required reply include (A) a statement from each person being added as an inventor and from each person being deleted as an inventor that any error in inventorship in the international application occurred without deceptive intention on his or her part; (B) the processing fee set forth in 37

CFR 1.17(i); and (C) the written consent of the assignee if an assignment has been executed by any of the original named inventors (see 37 CFR 3.73(b)).

Accordingly, included herein is a statement from Dr. Givens that the error in inventorship in the international application occurred without deceptive intention. No persons are being deleted as an inventor. Also included are the processing fee set forth in 37 CFR 1.17(i) and the written consent of the assignee to add Dr. Givens as an inventor.


**Item 2. Petition Fee.** The Decision stated Applicant has paid the required fee, Item 2 is satisfied, and no additional petition fee is required.

**Item 3. Statement Regarding Unintentional Delay.** The Decision stated that the filed petition for revival included the required statement and that Item 3 is satisfied.

**Item 4. Terminal disclaimer.** The Decision stated that this Item does not apply to the present application.

This Response is timely filed, within two months of the mailing date of the Decision. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed, or which should have been filed herewith or with any paper hereafter filed in this application by this firm to our Deposit Account No. 16-1445.

Respectfully submitted,

  
\_\_\_\_\_  
Timothy J. Gumbleton, Patent Agent  
Registration No. 54,143

Date: February 21, 2008

Pfizer Inc.  
Patent Department  
7000 Portage Road  
Kalamazoo, Michigan 49001  
Telephone No. (269) 833-2501  
Telefax No. (269) 833-8897

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Serial Number: 10/593,134

Int'l Serial Number: PCT/IB2005/000610

Priority Date: 17 March 2004

Int'l Filing Date: 4 March 2005

First Named Inventor: Michael A. Ellsworth

Atty Docket Number: PC32199A

For: Method of Vaccination Against Testicular BVDV Infection

Dated: 4 February 2008

OFFICE OF PCT LEGAL ADMINISTRATION

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**RENEWED PETITION UNDER 37 CFR 1.137(b)  
Consent of Assignee to Correction and/or Addition  
To Previously Named Inventors Under 37 CFR 1.48**

Sir:

Pharmacia & Upjohn Company, a Delaware corporation, with a place of business in New York, New York, assignee of the application as identified above by virtue of the assignment of the priority application US Serial Number 60/553,867:

Recorded assignments as follows:

<u>Date Executed</u>	<u>Date Recorded</u>	<u>Reel Frame</u>
April 30, 2004	August 9, 2004	014989/0276

hereby consents to the correction and/or change of inventorship from the previous designation of inventors, as follows:


Michael Aaron Ellsworth

Cassius McAllister Tucker;

to the corrected designation of inventors, as follows:

Michael Aaron Ellsworth  
Cassius McAllister Tucker  
Maurice Daniel Givens.

Respectfully submitted,



Grover F. Fuller, Jr.,  
**Assistant Secretary**  
Registration No. 31,760

Date: FEB - 7 2008

Pfizer Inc.  
150 East 42<sup>nd</sup> Street  
New York, NY 10017  
Telephone: (212) 573-1390  
Facsimile: (212) 573-1939

Attachment: Recordation of Assignment  
Assignment



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231



AUGUST 16, 2004

PTAS

\*700103831A\*

PHARMACIA & UPJOHN  
DEBRA J. MARQUETTE  
GLOBAL INTELLECTUAL PROPERTY  
301 HENRIETTA STREET  
KALAMAZOO, MI 49007-0199

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/09/2004

REEL/FRAME: 014989/0276  
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).  
DOCKET NUMBER: 32199

## ASSIGNOR:

ELLSWORTH, MICHAEL A.

DOC DATE: 04/30/2004

## ASSIGNOR:

TUCKER, CASSIUS M.

DOC DATE: 04/30/2004

## ASSIGNEE:

PHARMACIA & UPJOHN COMPANY  
301 HENRIETTA STREET  
GLOBAL INTELLECTUAL PROPERTY  
KALAMAZOC, MICHIGAN 49001

SERIAL NUMBER: 60553867

FILING DATE: 03/17/2004

PATENT NUMBER:

ISSUE DATE:

TITLE: METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION




014989/0276 PAGE 2

TONYA LEE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

08/09/2004

PTO Assignment Office Fax: 703-306-5996/700103831

PATENT/Docket No.: 32199

PATENTS ONLY		PATENTS ONLY	
To the Honorable Commissioner of Patents & Trademarks Please record the attached original document or copy thereof.			
1. Name of Party(ies) conveying an interest: Michael A. Ellsworth; Cassius M. Tucker		2. Name and address of Party(ies) receiving an interest:  Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, MI 49001	
3. Description of the interest conveyed:  <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agmt <input type="checkbox"/> Change of Name <input type="checkbox"/> Other  Execution Date: 30 April 2004			
4. Application number(s) or patent number(s). Additional sheet attached <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If this document is being filed together with a new application, the execution date of the application is: _____ date			
A. Patent Application No.(s) 60/553,867 filed on 17 March 2004		B. Patent No.(s)	
5. Name and address of party to whom correspondence concerning this document should be faxed:  Debra J. Marquette, Legal Assistant Pharmacia & Upjohn, 0228-32-LAW Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49007-0199  Fax Number 269-833-8897		6. Number of applications and patents involved:  One	
		7. Amount of fee enclosed or authorized to be charged: \$40.00	
		8. Deposit account number: 21-0718	
DO NOT USE THIS SPACE			
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.   _____ (Signature)  Debra J. Marquette Name of Person Signing  Date: August 9, 2004			

CH \$40.00 210718 60553867

**ASSIGNMENT**

**Title:** Method of Vaccination Against Testicular BVDV Infection  
**Inventors:** Michael A. Ellsworth; Cassius M. Tucker  
**Serial No.:** 60/553,867      **Filing Date:** March 17, 2004  
**Docket No.** 32199      **Country:** US  
**Execution Date of Application:**

As a below-named inventor, I hereby declare that:

My post office address is as stated below under my signature and I am named as inventor of the inventions or discoveries (herein INVENTIONS) as described in the patent application (herein APPLICATION) identified above. In view of valuable consideration, receipt thereof is hereby acknowledged, I do hereby assign and transfer unto PHARMACIA & UPJOHN COMPANY, a corporation of the State of Delaware having a place of business at Kalamazoo, Michigan, its successors and assigns, my entire interest in and the full and exclusive right to the INVENTIONS, the APPLICATION and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (herein PATENTS) which may be granted based upon the INVENTIONS or the APPLICATION or related applications or counterparts in other countries; said transfer and assignment being applicable throughout the world. I hereby authorize and request officials of patent offices in any and all countries of the world to issue any and all of the PATENTS, when granted, to PHARMACIA & UPJOHN COMPANY, its successors and assigns, as the assignee of my entire right, title, and interest in and to the same. I agree that I will communicate to PHARMACIA & UPJOHN COMPANY, or its representatives, any facts known to me respecting the invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of the PATENTS to be issued to PHARMACIA & UPJOHN COMPANY; make all rightful oaths; and generally do everything possible to aid PHARMACIA & UPJOHN COMPANY, its successors and assigns, to obtain and enforce proper protection for the INVENTION in any and all countries throughout the world. I hereby authorize and request the attorneys of record in said application to insert in this assignment the execution date and/or filing date and serial number of said application when officially known.

FULL NAME OF FIRST/SOLE INVENTOR: Michael A. Ellsworth

Signature of Inventor: Michael A. Ellsworth


Address: 5510 Thistle Circle, Lincoln, Nebraska 68516

STATE OF NEBRASKA

COUNTY OF Lancaster

On April 30, 2004, the above named inventor personally appeared before me and executed the foregoing instrument and acknowledged the same to be his/her free act and deed in and for the purposes set forth in said instrument.

SEAL



Denise Cheri Minchew  
Notary Public

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Serial Number: 10/593,134

Int'l Serial Number: PCT/IB2005/000610

Priority Date: 17 March 2004

Int'l Filing Date: 4 March 2005

First Named Inventor: Michael A. Ellsworth

Atty Docket Number: PC32199A

For: METHOD OF VACCINATION AGAINST TESTICULAR BVDV  
INFECTION

Dated: 4 February 2008

OFFICE OF PCT LEGAL ADMINISTRATION  
Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RENEWED PETITION UNDER 37 CFR 1.137(b)**  
**Statement in Support of Petition to Correct**  
**Inventorship in a US National Stage Application**

Sir:

This statement is provided in support of the Petition to Correct Inventorship in the above-referenced application. The published international application identified two applicant/inventors for the United States: Michael Aaron Ellsworth and Cassius McAllister Tucker. However, I believe that I was also an inventor and this application should also include my name.

The omission of my name as a co-inventor on the above-identified international patent application occurred as the result of an error without any deceptive intention on my part.

Respectfully submitted,



Maurice Daniel Givens  
138 Plantation Way  
Auburn, Alabama 36832

Date: 08 Feb 08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	PC32199A
		Application Number	10/593134
Title of Invention	METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

**Secrecy Order 37 CFR 5.2**

<input type="checkbox"/>	Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--------------------------	---

**Applicant Information:**

<b>Applicant 1</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Michael	A.	Ellsworth	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Lincoln	<b>State/Province</b>	NE	<b>Country of Residence i</b> US
<b>Citizenship under 37 CFR 1.41(b) i</b>		US		
<b>Mailing Address of Applicant:</b>				
<b>Address 1</b>		5510 Thistle Ct.		
<b>Address 2</b>				
<b>City</b>	Lincoln	<b>State/Province</b>	NE	
<b>Postal Code</b>	68516	<b>Country i</b>	US	
<b>Applicant 2</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Cassius	M.	Tucker	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Kalamazoo	<b>State/Province</b>	MI	<b>Country of Residence i</b> US
<b>Citizenship under 37 CFR 1.41(b) i</b>		US		
<b>Mailing Address of Applicant:</b>				
<b>Address 1</b>		2140 Waite Avenue		
<b>Address 2</b>				
<b>City</b>	Kalamazoo	<b>State/Province</b>	MI	
<b>Postal Code</b>	49008	<b>Country i</b>	US	
<b>Applicant 3</b>				
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
	Maurice	D.	Givens	
<b>Residence Information (Select One)</b> <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
<b>City</b>	Auburn	<b>State/Province</b>	AL	<b>Country of Residence i</b> US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	PC32199A
		Application Number	10   593134
Title of Invention	METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION		

Citizenship under 37 CFR 1.41(b) i		US	
Mailing Address of Applicant:			
Address 1	138 Plantation Way		
Address 2			
City	Auburn	State/Province	AL
Postal Code	36832	Country	US
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.			<input type="button" value="Add"/>

**Correspondence Information:**

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.			
Customer Number	25533		
Email Address		<input type="button" value="Add Email"/>	<input type="button" value="Remove Email"/>

**Application Information:**

Title of the Invention	METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION		
Attorney Docket Number	PC32199A	Small Entity Status Claimed	<input type="checkbox"/>
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	
Publication Information:			
<input type="checkbox"/> Request Early Publication (Fee required at time of Request 37 CFR 1.219)			
<input type="checkbox"/> Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.			

**Representative Information:**

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.			
Please Select One:	<input checked="" type="radio"/> Customer Number	<input type="radio"/> US Patent Practitioner	<input type="radio"/> US Representative (37 CFR 11.9)

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	PC32199A
		Application Number	10/593134
Title of Invention	METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION		
Customer Number	25533		

### Domestic Priority Information:

This section allows for the applicant to claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c). Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status	Pending	<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
10/593134	a 371 of international	PCT/IB05/000610	2005-03-04
Prior Application Status	Abandoned	<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
PCT/IB05/000610	non provisional of	60/553867	2004-03-17
Additional Domestic Priority Data may be generated within this form by selecting the <b>Add</b> button.			

### Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

<a href="#">Remove</a>		
Application Number	Country <sup>i</sup>	Parent Filing Date (YYYY-MM-DD)
		Priority Claimed <input type="radio"/> Yes <input checked="" type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the <b>Add</b> button.		

### Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.

<b>Assignee 1</b>			
If the Assignee is an Organization check here. <input checked="" type="checkbox"/>			
Organization Name	Pharmacia & Upjohn Company		
<b>Mailing Address Information:</b>			
Address 1			
Address 2			
City	Kalamazoo	State/Province	MI
Country <sup>i</sup>	US	Postal Code	49001
Phone Number		Fax Number	
Email Address			
Additional Assignee Data may be generated within this form by selecting the <b>Add</b> button.			




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	PC32199A
		Application Number	10 / 593134
Title of Invention	METHOD OF VACCINATION AGAINST TESTICULAR BVDV INFECTION		

**Signature:**

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.

<b>Signature</b>	/Timothy J. Gumbleton/ 		Date (YYYY-MM-DD)	2008-02-21	
First Name	Timothy	Last Name	Gumbleton	Registration Number	54143

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.